Gapping down
In reaction to disappointing earnings/guidance:
- CRR -31.4%
Select China related names showing weakness:
- BZUN -1.4%, JD -1.2%, WB -1.2%, SINA -1%, BIDU -0.9%, CAT -0.8%
Select metals/mining stocks trading lower:
- RIO -3.4%, BBL -2.8%, BHP -2.2%, CLF -1.7%, X -1%
Other news:
- NXTC -58.3% (reports clinical data from NC318 Phase 1/2 Clinical Trial)
- ASLN -18.3% (announces topline results from treetopp global pivotal study of varlitinib in biliary tract cancer; study did not meet its co-primary endpoints)
- FOMX -16.8% (Foamix and Menlo Therapeutics (MNLO) to merge; Foamix stock will be exchanged for 0.5924 of a share of Menlo common stock and a contingent stock right)
- TUP -9.5% (suspends quarterly dividend)
- ARGX -5.5% (entered into $20 mln common stock sales agreement with H.C. Wainwright)
- FTSI -4.6% (files for ~76.4 mln share common stock offering by holders)
- MUX -3% (files for 300K share common stock offering by holders)
- MYOK -1.7% (announced topline data from MAVERICK-HCM, the company's Phase 2 clinical trial of mavacamten in patients with non-obstructive hypertrophic cardiomyopathy) .
Analyst comments:
- SMAR -6.9% (downgraded to Neutral from Outperform at Wedbush)
- GDOT -5.6% (downgraded to Neutral from Buy at Guggenheim)
- LITE -3.8% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- ACRX -3.6% (downgraded to Neutral from Outperform at Credit Suisse)
- RLGY -2.9% (downgraded to Negative from Neutral at Susquehanna)
- QCOM -1.6% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- CSCO -1.3% (downgraded to Neutral from Overweight at Piper Jaffray)
- HD -1% (downgraded to Hold from Buy at Edward Jones)